{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T16:17:45Z","timestamp":1789834665688,"version":"4.0.1"},"reference-count":102,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T00:00:00Z","timestamp":1604880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","award":["1403\/14"],"award-info":[{"award-number":["1403\/14"]}],"id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Laron syndrome (LS) is a rare genetic endocrinopathy that results from mutation of the growth hormone receptor (GH-R) gene and is typically associated with dwarfism and obesity. LS is the best characterized entity under the spectrum of the congenital insulin-like growth factor-1 (IGF1) deficiencies. Epidemiological analyses have shown that LS patients do not develop cancer, whereas heterozygous family members have a cancer prevalence similar to the general population. To identify genes and signaling pathways differentially represented in LS that may help delineate a biochemical and molecular basis for cancer protection, we have recently conducted a genome-wide profiling of LS patients. Studies were based on our collection of Epstein\u2013Barr virus (EBV)-immortalized lymphoblastoid cell lines derived from LS patients, relatives and healthy controls. Bioinformatic analyses identified differences in gene expression in several pathways, including apoptosis, metabolic control, cytokine biology, Jak-STAT and PI3K-AKT signaling, etc. Genes involved in the control of cell cycle, motility, growth and oncogenic transformation are, in general, down-regulated in LS. These genetic events seem to have a major impact on the biological properties of LS cells, including proliferation, apoptosis, response to oxidative stress, etc. Furthermore, genomic analyses allowed us to identify novel IGF1 downstream target genes that have not been previously linked to the IGF1 signaling pathway. In summary, by \u2018mining\u2019 genomic data from LS patients, we were able to generate clinically-relevant information in oncology and, potentially, related disciplines.<\/jats:p>","DOI":"10.3390\/cells9112446","type":"journal-article","created":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T19:08:29Z","timestamp":1604948909000},"page":"2446","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Laron Syndrome Research Paves the Way for New Insights in Oncological Investigation"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0154-1290","authenticated-orcid":false,"given":"Haim","family":"Werner","sequence":"first","affiliation":[{"name":"Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel"},{"name":"Shalom and Varda Yoran Institute for Human Genome Research, Tel Aviv University, Tel Aviv 69978, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rive","family":"Sarfstein","sequence":"additional","affiliation":[{"name":"Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5295-4808","authenticated-orcid":false,"given":"Karthik","family":"Nagaraj","sequence":"additional","affiliation":[{"name":"Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zvi","family":"Laron","sequence":"additional","affiliation":[{"name":"Endocrine and Diabetes Research Unit, Schneider Children\u2019s Medical Center, Petah Tikva 49292, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,11,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/ncpendmet0427","article-title":"Mechanisms of disease: Metabolic effects of growth hormone and insulin-like growth factor-1","volume":"3","author":"LeRoith","year":"2007","journal-title":"Nat. Clin. Pract. Endocrinol. Metab."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ecl.2012.04.008","article-title":"Insulin-like growth factor 1 physiology: Lessons from mouse models","volume":"41","author":"Yakar","year":"2012","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"ref_3","first-page":"825","article-title":"A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro","volume":"49","author":"Salmon","year":"1957","journal-title":"J. Lab. Clin. Med."},{"key":"ref_4","first-page":"113","article-title":"Insulin-like growth factors and breast cancer","volume":"21","author":"Bentov","year":"2009","journal-title":"Curr. Med. Lit.-Breast Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1126\/science.1077991","article-title":"Evolutionary medicine: From dwarf model systems to healthy centenarians?","volume":"299","author":"Longo","year":"2003","journal-title":"Science"},{"key":"ref_6","first-page":"352","article-title":"IGF, IGF receptor and overgrowth syndromes","volume":"1","author":"Bentov","year":"2004","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/ijc.11487","article-title":"The IGF-1 receptor in cancer biology","volume":"107","author":"Baserga","year":"2003","journal-title":"Int. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1073\/pnas.89.9.3889","article-title":"Ras proteins are essential and selective for the action of insulin-like growth factor 1 late in the G1 phase of the cell cycle in BALB\/c murine fibroblasts","volume":"89","author":"Lu","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1159\/000066230","article-title":"The role of the IGF system in cancer: From basic to clinical studies and clinical applications","volume":"63","author":"Moschos","year":"2002","journal-title":"Oncology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1038\/onc.2011.447","article-title":"Tumor suppressors govern insulin-like growth factor signaling pathways: Implications in metabolism and cancer","volume":"31","author":"Werner","year":"2012","journal-title":"Oncogene"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.1038\/sj.onc.1203854","article-title":"The contradictions of the insulin-like growth factor 1 receptor","volume":"19","author":"Baserga","year":"2000","journal-title":"Oncogene"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1080\/13813450902783106","article-title":"The insulin-like growth factor-I receptor as an oncogene","volume":"115","author":"Werner","year":"2009","journal-title":"Arch. Physiol. Biochem."},{"key":"ref_13","first-page":"3739","article-title":"Correlation between apoptosis, tumorigenesis, and levels of insulin-like growth factor I receptors","volume":"55","author":"Resnicoff","year":"1995","journal-title":"Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"6364","DOI":"10.1158\/1078-0432.CCR-07-4879","article-title":"The type I insulin-like growth factor-I receptor pathway","volume":"14","author":"Chitnis","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1006\/mgme.2000.3044","article-title":"Regulation of the insulin-like growth factor-I receptor gene by oncogenes and antioncogenes: Implications in human cancer","volume":"71","author":"Werner","year":"2000","journal-title":"Mol. Gen. Metab."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.mce.2006.03.018","article-title":"Transcriptional regulation of the insulin-like growth factor-1 receptor in breast cancer","volume":"252","author":"Sarfstein","year":"2006","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Holly, J.M.P., Biernacka, K., and Perks, C.M. (2019). The neglected insulin: IGF-II, a metabolic regulator with implications for diabetes, obesity, and cancer. Cells, 8.","DOI":"10.3390\/cells8101207"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5948","DOI":"10.2174\/1381612822666160713100235","article-title":"Insulin-like growth factor 2\u2014The oncogene and its accomplices","volume":"22","author":"Kessler","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"ref_19","first-page":"521","article-title":"Insulin-like growth factor binding proteins\u2014An update","volume":"13","author":"Bach","year":"2015","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrc3720","article-title":"IGF binding proteins in cancer: Mechanistic and clinical insights","volume":"14","author":"Baxter","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.tem.2008.03.003","article-title":"IGF signaling defects as causes of growth failure and IUGR","volume":"19","author":"Klammt","year":"2008","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.ghir.2005.06.014","article-title":"The molecular basis of idiophatic short stature","volume":"15","author":"Rosenfeld","year":"2005","journal-title":"Growth Horm. IGF Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1530\/EC-17-0038","article-title":"A novel heterozygous IGF-1 receptor mutation associated with hypoglycemia","volume":"6","author":"Steier","year":"2017","journal-title":"Endocr. Connect."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1210\/jc.2008-0509","article-title":"2007 ISS Consensus Workshop participants. Consensus statement on the diagnosis and treatment of children with idiopathis short stature: A summary of the Growth Hormone Research Society, The Lawson Wilkins Pediatric Endocrine Society and the European Society for Pediatric Endocrinology Workshop","volume":"93","author":"Cohen","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJM199610313351805","article-title":"Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene","volume":"335","author":"Woods","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1056\/NEJMoa013100","article-title":"Deficiency of the circulating IGF system associated with inactivation of the acid-labile subunit gene","volume":"350","author":"Domene","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_27","first-page":"39","article-title":"Genetic mutations in the GH\/IGF axis","volume":"16","year":"2018","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa022926","article-title":"Growth hormone insensitivity associated with a STAT5b mutation","volume":"349","author":"Kofoed","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.15252\/emmm.201707950","article-title":"One level up: Abnormal proteolytic regulation of IGF activity plays a role in human pathophysiology","volume":"9","author":"Argente","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"363","DOI":"10.15252\/emmm.201506106","article-title":"Mutations in pregnancy-associated plasma protein A2 cause short stature due to low IGF-I availability","volume":"8","author":"Dauber","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0092-8674(05)80085-6","article-title":"Role of insulin-like growth factors in embryonic and postnatal growth","volume":"75","author":"Baker","year":"1993","journal-title":"Cell"},{"key":"ref_32","first-page":"59","article-title":"Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r)","volume":"75","author":"Liu","year":"1993","journal-title":"Cell"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1006\/dbio.2000.9975","article-title":"Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth","volume":"229","author":"Lupu","year":"2001","journal-title":"Dev. Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"7324","DOI":"10.1073\/pnas.96.13.7324","article-title":"Normal growth and development in the absence of hepatic insulin-like growth factor I","volume":"96","author":"Yakar","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1210\/en.2013-2086","article-title":"Liver-specific GH receptor gene-disrupted (LiGHRKO) mice have decreased endocrine IGF-I, increased local IGF-I, and altered body size, body composition, and adipokine profiles","volume":"155","author":"List","year":"2014","journal-title":"Endocrinology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"T45","DOI":"10.1530\/JME-17-0250","article-title":"IGF system in sarcomas: A crucial pathway with many unknowns to exploit for therapy","volume":"61","author":"Mancarella","year":"2018","journal-title":"J. Mol. Endocrinol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/S0140-6736(97)10384-1","article-title":"Circulating concentrations of insulin-like growth factor-I and risk of breast cancer","volume":"351","author":"Hankinson","year":"1998","journal-title":"Lancet"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1126\/science.279.5350.563","article-title":"Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study","volume":"279","author":"Chan","year":"1998","journal-title":"Science"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1093\/jnci\/91.7.620","article-title":"Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3","volume":"91","author":"Ma","year":"1999","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1677\/joe.0.1620321","article-title":"Growth hormone, IGF-I and cancer. Less intervention to avoid cancer? More intervention to prevent cancer?","volume":"162","author":"Holly","year":"1999","journal-title":"J. Endocrinol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1046\/j.1365-2362.1998.00247.x","article-title":"In vitro effects of growth hormone (GH) and insulin-like growth factor I and II (IGF-I and -II) on chromosome fragility and p53 protein expression in human lymphocytes","volume":"28","author":"Cianfarani","year":"1998","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1126\/science.2204108","article-title":"Cell proliferation in carcinogenesis","volume":"249","author":"Cohen","year":"1990","journal-title":"Science"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.4158\/EP15939.RA","article-title":"Lessons from 50 years of study of Laron syndrome","volume":"21","author":"Laron","year":"2015","journal-title":"Endocr. Pract."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1210\/jc.2003-031033","article-title":"Extensive personal experience. Laron syndrome (primary growth hormone resistance or insensitivity): The personal experience 1958\u20132003","volume":"89","author":"Laron","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Laron, Z., and Kopchik, J.J. (2011). Laron Syndrome\u2014From Man to Mouse, Springer.","DOI":"10.1007\/978-3-642-11183-9"},{"key":"ref_46","first-page":"6","article-title":"Fifty years on: New lessons from Laron syndrome","volume":"19","author":"Werner","year":"2017","journal-title":"Isr. Med. Assoc. J."},{"key":"ref_47","first-page":"152","article-title":"Genetic pituitary dwarfism with high serum concentration of growth hormone-a new inborn error of metabolism?","volume":"2","author":"Laron","year":"1966","journal-title":"Isr. J. Med. Sci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1210\/edrv-15-3-369","article-title":"Growth hormone insensitivity due to primary GH receptor deficiency","volume":"15","author":"Rosenfeld","year":"1994","journal-title":"Endocr. Rev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/199784a0","article-title":"Immunoassay of human growth hormone in plasma","volume":"199","author":"Glick","year":"1963","journal-title":"Nature"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1210\/jcem-37-5-819","article-title":"Immunoreactive properties of the plasma hGH from patients with the syndrome of familial dwarfism with high plasma IR-hGH","volume":"37","author":"Eshet","year":"1973","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_51","first-page":"8","article-title":"Defects of human growth hormone receptors in the liver of two patients with Laron-type dwarfism","volume":"20","author":"Eshet","year":"1984","journal-title":"Isr. J. Med. Sci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"8083","DOI":"10.1073\/pnas.86.20.8083","article-title":"Characterization of the human growth hormone receptor gene and demonstration of a partial gene deletion in two patients with Laron-type dwarfism","volume":"86","author":"Godowski","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJM198910123211501","article-title":"Laron dwarfism and mutations of the growth hormone-receptor gene","volume":"321","author":"Amselem","year":"1989","journal-title":"N. Engl. J. Med."},{"key":"ref_54","first-page":"489","article-title":"Genetic analysis of the pedigrees and molecular defects of the GH-receptor gene in the Israeli cohort of patients with Laron syndrome","volume":"3","author":"Shevah","year":"2006","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S1043-2760(98)00070-8","article-title":"Lessons from the genetics of Laron syndrome","volume":"9","author":"Rosenbloom","year":"1998","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1002\/ajmg.a.36444","article-title":"The E180 splice mutation in the GHR gene causing Laron syndrome: Witness of a Sephardic Jewish exodus from the Iberian Peninsula to the New World?","volume":"164","author":"Goncalves","year":"2014","journal-title":"Am. J. Med. Genet."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"13215","DOI":"10.1073\/pnas.94.24.13215","article-title":"A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor\/binding protein gene (the Laron mouse)","volume":"94","author":"Zhou","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_58","first-page":"629","article-title":"Two year treatment of GH receptor deficiency with recombinant IGF-I in 22 children: Comparison of two dosage levels and to GH treated GH deficiency","volume":"82","author":"Rosenbloom","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_59","first-page":"1504","article-title":"Therapy for 6.5\u20137.5 years with recombinant IGF-I in children with growth hormone insensitivity syndrome: A clinical research center study","volume":"86","author":"Backeljauw","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1651-2227.2000.tb01184.x","article-title":"Comparison of the growth promoting effects of IGF-I and growth hormone in the early years of life","volume":"88","author":"Laron","year":"2000","journal-title":"Acta Paediatr."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"6657","DOI":"10.4081\/tmr.6657","article-title":"Genome-wide profiling of congenital IGF1 deficient patients: Translational implications in cancer prevention and metabolism","volume":"1","author":"Werner","year":"2017","journal-title":"Transl. Med. Rep."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ghir.2006.10.007","article-title":"Patients with congenital deficiency of IGF-I seem protected from the development of malignancies: A preliminary report","volume":"17","author":"Shevah","year":"2007","journal-title":"Growth Horm. IGF Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1530\/EJE-10-0859","article-title":"Congenital IGF1 deficiency tends to confer protection against post-natal development of malignancies","volume":"164","author":"Steuerman","year":"2011","journal-title":"Eur. J. Endocrinol."},{"key":"ref_64","first-page":"70ra13","article-title":"Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans","volume":"3","author":"Balasubramanian","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.1210\/en.2005-0607","article-title":"Disruption of growth hormone signaling retards early stages of prostate carcinogenesis in the C3(1)\/T antigen mouse","volume":"146","author":"Wang","year":"2005","journal-title":"Endocrinology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1158\/0008-5472.CAN-07-6271","article-title":"Reduced susceptibility to two-stage skin carcinogenesis in mice with low circulating insulin-like growth factor-I levels","volume":"68","author":"Moore","year":"2008","journal-title":"Cancer Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1530\/ERC-16-0054","article-title":"Identification of signaling pathways associated with cancer protection in Laron syndrome","volume":"23","author":"Rotem","year":"2016","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2217\/pgs.10.27","article-title":"Human lymphoblastoid cell line panels: Novel tools for assessing shared drug pathways","volume":"11","author":"Morag","year":"2010","journal-title":"Pharmacogenomics"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Vidal, A.C., Tucker, C., Schildkraut, J.M., Richardson, R.M., McPhail, M., Freedland, S.J., Hoyo, C., and Grant, D.J. (2013). Novel associations of UDP-glucuronosyltransferase 2B gene variants with prostate cancer risk in a multiethnic study. BMC Cancer, 13.","DOI":"10.1186\/1471-2407-13-556"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.bcp.2018.08.003","article-title":"Quantitative characterization of UDP-glucuronosyltransferase 2B17 in human liver and intestine and its role in testosterone first-pass metabolism","volume":"156","author":"Zhang","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.18632\/oncotarget.27055","article-title":"Identification of ZYG11A as a candidate IGF1-dependent proto-oncogene in endometrial cancer","volume":"10","author":"Achlaug","year":"2019","journal-title":"Oncotarget"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejca.2020.09.034","article-title":"Identification of nephronectin as a new target for IGF1 action","volume":"141","author":"Sarfstein","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1093\/carcin\/bgr031","article-title":"The multiple roles of autophagy in cancer","volume":"32","author":"Rosenfeldt","year":"2011","journal-title":"Carcinogenesis"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"542","DOI":"10.4161\/auto.4600","article-title":"How to interpret LC3 immunoblotting","volume":"3","author":"Mizushima","year":"2007","journal-title":"Autophagy"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.cell.2009.05.023","article-title":"p62 at the crossroads of autophagy, apoptosis, and cancer","volume":"137","author":"Moscat","year":"2009","journal-title":"Cell"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"21884","DOI":"10.1074\/jbc.M600427200","article-title":"The interaction of thioredoxin with Txnip: Evidence for formation of a mixed disulfide by disulfide exchange","volume":"281","author":"Patwari","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/0167-4781(94)90242-9","article-title":"Isolation and characterization of a novel cDNA from HL-60 cells treated with 1,25-dihydroxyvitamin D-3","volume":"1219","author":"Chen","year":"1994","journal-title":"Biochim. Biophys. Acta Gene Struct. Expr."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/ars.2000.2.1-83","article-title":"Thioredoxin inhibits tumor necrosis factor- or interleukin-1-induced NF-kappaB activation at a level upstream of NF-kappaB-inducing kinase","volume":"2","author":"Takeuchi","year":"2000","journal-title":"Antioxid. Redox Signal."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"6835","DOI":"10.1074\/jbc.M112.419101","article-title":"Thioredoxin-interacting protein mediates high glucose-induced reactive oxygen species generation by mitochondria and the NADPH oxidase, Nox4, in mesangial cells","volume":"288","author":"Shah","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.4049\/jimmunol.164.12.6287","article-title":"Vitamin D3 up-regulated protein 1 mediates oxidative stress via suppressing the thioredoxin function","volume":"164","author":"Junn","year":"2000","journal-title":"J. Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1073\/pnas.1715930115","article-title":"Identification of thioredoxin-interacting protein (TXNIP) as a downstream target for IGF1 action","volume":"115","author":"Nagaraj","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1089\/ars.2011.4137","article-title":"Thioredoxin interacting protein: Redox dependent and independent regulatory mechanisms","volume":"16","author":"Spindel","year":"2012","journal-title":"Antioxid. Redox Signal."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.cmet.2020.07.002","article-title":"Identification of an anti-diabetic, orally available small molecule that regulates TXNIP expression and glucagon action","volume":"32","author":"Thielen","year":"2020","journal-title":"Cell Metab."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ghir.2017.11.004","article-title":"Differential expression of IGFBPs in Laron syndrome-derived lymphoblastoid cell lines: Potential correlation with reduced cancer incidence","volume":"39","author":"Somri","year":"2018","journal-title":"Growth Horm. IGF Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.humimm.2004.10.014","article-title":"Effects of insulin-like growth factors and insulin-like growth factor binding protein-2 on the in vitro proliferation of peripheral blood mononuclear cells","volume":"66","author":"Hettmer","year":"2005","journal-title":"Hum. Immunol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1165\/rcmb.2008-0211OC","article-title":"The pro-fibrotic factor IGFBP-5 induces lung fibroblast and mononuclear cell migration","volume":"41","author":"Yasuoka","year":"2009","journal-title":"Am. J. Respir. Cell. Mol. Biol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"60826","DOI":"10.18632\/oncotarget.18338","article-title":"Human monocyte-derived dendritic cells exposed to hyperthermia show a distinct gene expression profile and selective upregulation of IGFBP6","volume":"8","author":"Liso","year":"2017","journal-title":"Oncotarget"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1038\/sj.onc.1209977","article-title":"Insulin-like growth factor-binding protein-3 inhibition of prostate cancer growth involves suppression of angiogenesis","volume":"26","author":"Liu","year":"2007","journal-title":"Oncogene"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1210\/jcem.74.4.1372321","article-title":"Expression of serum insulin-like growth factors, insulin-like growth factor-binding proteins, and the growth hormone-binding protein in heterozygote relatives of Ecuadorian growth hormone receptor deficient patients","volume":"74","author":"Fielder","year":"1992","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_90","first-page":"56","article-title":"The insulin-like growth factor (IGF)-binding proteins and IGF bioactivity in Laron-type dwarfism","volume":"74","author":"Cotterill","year":"1992","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_91","first-page":"144","article-title":"Long-term treatment of Laron type dwarfs with insulin-like growth factor-1 increases serum IGF-binding protein-3 in the absence of growth hormone activity","volume":"128","author":"Kanety","year":"1993","journal-title":"Acta Endocrinol."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Laron, Z., and Kopchik, J. (2011). IGF-I binding proteins in Laron syndrome. Laron Syndrome: From Man to Mouse, Springer.","DOI":"10.1007\/978-3-642-11183-9_27"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3389\/fonc.2016.00159","article-title":"Insulin-like growth factor 1 signaling axis meets p53 genome protection pathways","volume":"6","author":"Werner","year":"2016","journal-title":"Front. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrc3711","article-title":"Unravelling mechanisms of p53-mediated tumour suppression","volume":"14","author":"Bieging","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nrm4007","article-title":"p53 in survival, death and metabolic health: A lifeguard with a licence to kill","volume":"16","author":"Kruiswijk","year":"2015","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1055\/s-2004-814154","article-title":"Functional and physical interactions between BRCA1 and p53 in transcriptional regulation of the IGF-IR gene","volume":"35","author":"Abramovitch","year":"2003","journal-title":"Horm. Metab. Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1016\/j.ejca.2011.09.014","article-title":"p53 regulates insulin-like growth factor-I receptor gene expression in uterine serous carcinoma and predicts responsiveness to an insulin-like growth factor-I receptor-directed targeted therapy","volume":"48","author":"Bentov","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"8318","DOI":"10.1073\/pnas.93.16.8318","article-title":"Wild type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene","volume":"93","author":"Werner","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.ghir.2005.07.005","article-title":"The p53-family members p63 and p73 inhibit insulin-like growth factor-I receptor gene expression in colon cancer cells","volume":"15","author":"Nahor","year":"2005","journal-title":"Growth Horm. IGF Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"15600","DOI":"10.1074\/jbc.M111142200","article-title":"Insulin-like growth factor I induces MDM2-dependent degradation of p53 via the p38 MAPK pathway in response to DNA damage","volume":"277","author":"LeRoith","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"8247","DOI":"10.1073\/pnas.1431613100","article-title":"Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor-I receptor","volume":"100","author":"Girnita","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_102","first-page":"5278","article-title":"Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: Functional impact","volume":"60","author":"Girnita","year":"2000","journal-title":"Cancer Res."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/9\/11\/2446\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:31:19Z","timestamp":1760178679000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/9\/11\/2446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,9]]},"references-count":102,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11]]}},"alternative-id":["cells9112446"],"URL":"https:\/\/doi.org\/10.3390\/cells9112446","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,9]]}}}